Commercial strategy and support for pharma brands and markets

  • Launch feasibility of potential new brands, long range forecasting, P&L build
  • Go-to-market strategy for new businesses or new markets
  • Marketing strategy for new brands or new indications
  • Strategic reviews of established brands in the face of market changes
  • Repositioning of mature brands to drive growth
  • Portfolio assessment and optimisation

Every case is different but despite that, there are certain vital building blocks to optimise results which we follow at Hawk Pharma Consulting:

It is critical to understand the market and the environment to understand how to progress your brand in a focused way, and with what objectives.  If this is an existing medicine that needs a boost, an accurate diagnosis is paramount as fully understanding the challenges will drive the right solution.

Start with the end in mind.  A forecast based on deep insight and then building a P&L will establish the viability of the brand or business.  To ensure best decisions are made there needs to be clear, quantified, SMART objectives plus critical success factors that capture vital qualitative elements.

We must create value for all stakeholders. Clear positioning and a strong value proposition for that brand, in that indication, in that market with those competitors is vital. We will develop a succinct, logical strategy for your brand.

From key messages, to marketing / medical / sales mix delivered with an omnichannel approach, the tactics must all deliver the strategy and in turn the KPIs and objectives.  We ensure this alignment of tactical execution.

A word from our Managing Director

“Small is beautiful”, says David Browne, Hawk Pharma Consulting Managing Director & Lead Consultant, “I say that because what we deliver, and how we deliver it and work with you, matters personally to me.  When others are involved, you can be sure that this is for their specific expertise and that I remain actively involved.  In my experience I haven’t always found this to be the case with some larger firms”.

David Browne, Hawk Pharma Consulting Managing Director & Lead Consultant